The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta‐Analysis of the European Myeloma Network ( <scp>EMN</scp> )
ABSTRACT We performed a comprehensive review with meta‐ and network meta‐analyzes of maintenance‐therapy studies. Lenalidomide, proteasome inhibitors, and CD38 antibodies improved progression‐free survival (PFS). However, overall survival (OS) benefit appeared only with lenalidomide in transplant‐eligible (TE) patients, while CD38‐directed therapy showed a trend toward improved OS not seen with proteasome inhibitors. The network meta‐analysis ranked regimens against observation: daratumumab–lenalidomide (DR) yielded the greatest PFS benefit, followed by carfilzomib–lenalidomide–dexamethasone (KRd), KR in TE, and DRd in transplant‐ineligible patients. Significant OS prolongation in TE patients occurred with KR, DR, and lenalidomide alone.
Authors
- Pieter Sonneveld (ORCID: https://orcid.org/0000-0002-0808-2237)
- Enrique M. Ocio (ORCID: https://orcid.org/0000-0002-5765-0085)
- Martin Schreder (ORCID: https://orcid.org/0000-0002-1699-9715)
- Christoph Driessen (ORCID: https://orcid.org/0000-0002-1124-7303)
- Leo Rasche (ORCID: https://orcid.org/0000-0002-9536-9649)
- Heinz Ludwig (ORCID: https://orcid.org/0000-0002-3302-8726)
- María‐Victoria Mateos (ORCID: https://orcid.org/0000-0003-2390-1218)
- Cyrille Touzeau (ORCID: https://orcid.org/0000-0003-0275-2575)
- Monika Martha Engelhardt (ORCID: https://orcid.org/0000-0003-0405-1676)
- Annemiek Broijl (ORCID: https://orcid.org/0000-0002-0554-8003)
- Charlotte Pawlyn (ORCID: https://orcid.org/0000-0002-7190-0028)
- Pellegrino Musto
- Rakesh Popat (ORCID: https://orcid.org/0000-0001-6553-4618)
- Sonja Zweegman (ORCID: https://orcid.org/0000-0002-5011-1820)
- G Jackson
- Roman Hájek (ORCID: https://orcid.org/0000-0001-6955-6267)
- Meletios Dimopoulos
- Francesca Gay (ORCID: https://orcid.org/0000-0002-8619-412X)
- Niels W. C. J. van de Donk (ORCID: https://orcid.org/0009-0007-1251-4649)
- Mario Boccadoro
- Fredrik Schjesvold
- Hermann Einsele
- Meral Beksaç
- Evangelos Terpos
- Sarah Bernhard
- Gordon Cook
Institutions
- Oslo University Hospital (NO)
- University of Vienna (AT)
- Universidad de Cantabria (ES)
- University College London Hospitals NHS Foundation Trust (GB)
- Institute of Cancer Research (GB)
- Universidad de Salamanca (ES)
- University of Ostrava (CZ)
- Korea University (KR)
- National and Kapodistrian University of Athens (GR)
- Kantonsspital St. Gallen (CH)
- Newcastle College (GB)
- University Medical Center Freiburg (DE)
- Centre Hospitalier Universitaire de Nantes (FR)
- Leeds Trinity University (GB)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Wilhelminen Hospital (AT)
- Marqués de Valdecilla University Hospital (ES)
- Instituto de Investigación Marqués de Valdecilla (ES)
- Royal Marsden Hospital (GB)
- Universitätsklinikum Würzburg (DE)
- Torino e-district (IT)
- Instituto de Investigación Biomédica de Salamanca (ES)
- UCL Biomedical Research Centre (GB)
- Erasmus MC Cancer Institute (NL)
- Liv Hospital (TR)
- Korea University (JP)
- University College London (GB)
- University of Bari Aldo Moro (IT)
- University of Newcastle Australia (AU)
- Newcastle University (GB)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- American Journal of Hematology
- Published
- 2026-06-18
- DOI
- https://doi.org/10.1002/ajh.70397
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00